A brain tumor
is an abnormal growth of tissue in the brain which may be benign or malignant which cause damage to the brain and becomes life threatening. Severe headache, nausea, vomiting, blurred and double vision, personality or behavior changes, difficulties in hearing and speech are the symptoms of brain tumor. It occurs due to changes in DNA cells and exposure to radiation. Brain tumor is classified by grades such as Grade I, II, III and IV. Brain tumors are majorly classified into primary and secondary types. Technological advancements and increased R&D investments in the treatments and therapies for brain tumor propels the market growth during the forecast period 2016-2022. Brain tumor treatment market
is poised to grow with XX% CAGR during the forecast period and reach $XXm by 2022.
Type of treatment is recommended based upon on the type, size and location of brain tumor. Various treatments for curing brain tumor are surgery, radiation therapy, and chemotherapy, immunotherapy and so on which reduce the symptoms and slow down the tumor’s growth. Chemotherapy is an alternative to radiation therapy in children with brain tumors due to its side effects. Researchers have been developed new techniques of delivering radiation that target the brain tumor while protecting nearby healthy tissues. Presence of brain tumour can be detected by Neorological tests, MRI, CT and Angiogram. High-energy radiation prevents the growth of acoustic neuromas.
By geography, America stands first in cases of brain tumor followed by Europe, APAC and RoW. Nearly 7,00,000 people in the U.S. are suffering with primary brain tumor and central nervous system tumor. More than 28,000 children are estimated to be living with a brain tumor in the U.S. Sample companies profiled in this report are:
- Genetech Inc. (U.S.)
- Bristol Mayers squibb (U.S.)
- Hoffmann-La Roche (Switzerland)
- Astra Zeneca (India)
- Pfizer Inc. (U.S.)